Immunomedics (IMMU) Downgraded by ValuEngine to “Sell”

ValuEngine downgraded shares of Immunomedics (NASDAQ:IMMU) from a hold rating to a sell rating in a research report sent to investors on Monday morning.

IMMU has been the subject of several other reports. BidaskClub upgraded shares of Immunomedics from a hold rating to a buy rating in a research note on Wednesday, August 23rd. Zacks Investment Research raised shares of Immunomedics from a hold rating to a buy rating and set a $15.00 price target for the company in a report on Wednesday, October 4th. Finally, Jefferies Group set a $11.00 price target on shares of Immunomedics and gave the stock a buy rating in a report on Thursday, August 17th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. Immunomedics has an average rating of Buy and an average target price of $15.33.

Immunomedics (NASDAQ IMMU) traded down $1.48 on Monday, hitting $9.00. 5,863,900 shares of the company traded hands, compared to its average volume of 3,070,784. The company has a quick ratio of 0.74, a current ratio of 0.74 and a debt-to-equity ratio of -0.29. Immunomedics has a 1 year low of $3.16 and a 1 year high of $14.48.

In related news, insider Behzad Aghazadeh purchased 1,325,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The stock was bought at an average price of $10.47 per share, with a total value of $13,872,750.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Venbio Select Advisor Llc purchased 1,150,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 14th. The stock was bought at an average cost of $10.39 per share, with a total value of $11,948,500.00. The disclosure for this purchase can be found here. 6.60% of the stock is currently owned by insiders.

Institutional investors have recently added to or reduced their stakes in the company. Amalgamated Bank grew its holdings in shares of Immunomedics by 8.1% during the second quarter. Amalgamated Bank now owns 12,911 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 966 shares in the last quarter. Stephens Inc. AR purchased a new stake in shares of Immunomedics during the second quarter worth $115,000. Raymond James Financial Services Advisors Inc. grew its holdings in shares of Immunomedics by 11.4% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 14,400 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 1,473 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of Immunomedics by 99.3% during the second quarter. SG Americas Securities LLC now owns 20,719 shares of the biopharmaceutical company’s stock worth $183,000 after buying an additional 10,323 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of Immunomedics by 38.8% during the first quarter. Bank of America Corp DE now owns 33,707 shares of the biopharmaceutical company’s stock worth $218,000 after buying an additional 9,426 shares in the last quarter. 76.32% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Immunomedics (IMMU) Downgraded by ValuEngine to “Sell”” was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.com-unik.info/2017/12/05/immunomedics-immu-downgraded-by-valuengine-to-sell.html.

About Immunomedics

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

What are top analysts saying about Immunomedics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Immunomedics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit